All In Biotech

Drug Trial Radar · NCT05304767

An Extension Study to Assess Long-Term Safety and Tolerability of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of Schizophrenia

An Open-label Extension Study to Assess the Long-term Safety and Tolerability of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of Schizophrenia

Last checked: Nov 20, 2026Latest source record: Jul 31, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

290

Actual

Start

Mar 7, 2022

Primary completion

Mar 25, 2026

Study completion Mar 25, 2026

Sponsor

Lead sponsor
Karuna Therapeutics, Inc., a Bristol Myers Squibb companyBristol Myers Squibb (BMY)
Sponsor type
Industry
First posted
Mar 31, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 3, multicenter, 52-week, outpatient, open-label extension (OLE) study to evaluate the long-term safety and tolerability of adjunctive KarXT in subjects with schizophrenia with an inadequate response to their current antipsychotic treatment who previously completed the treatment period (Visit 8/Day 42 ± 3) of ARISE Study (KAR-012). The primary objective of the study is to assess the long-term safety and tolerability of adjunctive KarXT (a fixed dose combination of xanomeline and trospium chloride twice daily \[BID\]) in subjects with schizophrenia.

Conditions

  • Schizophrenia

Interventions

  • Xanomeline and Trospium Chloride CapsulesDrug

    KarXT 50 mg/20 mg BID KarXT 75mg/20 mg BID KarXT 100mg/20 mg BID KarXT 125mg/30 mg BID

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of treatment-emergent adverse events (TEAEs)Time frame: From initial dose to safety follow-up visit (54 weeks) or early termination

Locations

94 sites in 4 countries. Site status is shown where the registry gives one.

  • Local Institution - 161

    Phoenix, Arizona

  • Local Institution - 175

    Little Rock, Arkansas

  • Local Institution - 112

    Little Rock, Arkansas

  • Local Institution - 146

    Anaheim, California

  • Local Institution - 130

    Bellflower, California

  • Local Institution - 110

    Cerritos, California

  • Local Institution - 167

    Culver City, California

  • Local Institution - 127

    Garden Grove, California

  • Local Institution - 152

    La Habra, California

  • Local Institution - 126

    Lafayette, California

  • Local Institution - 131

    Lemon Grove, California

  • Local Institution - 181

    Oceanside, California

  • Local Institution - 150

    Orange, California

  • Local Institution - 170

    Pico Rivera, California

  • Local Institution - 144

    Riverside, California

  • Local Institution - 164

    Stanford, California

  • Local Institution - 109

    Torrance, California

  • Local Institution - 186

    Coral Gables, Florida

  • Local Institution - 182

    Hialeah, Florida

  • Local Institution - 133

    Hialeah, Florida

  • Local Institution - 105

    Lauderhill, Florida

  • Local Institution - 145

    Miami, Florida

  • Local Institution - 171

    Miami, Florida

  • Local Institution - 173

    Miami Lakes, Florida

  • Local Institution - 153

    Miami Lakes, Florida

  • Local Institution - 156

    Pembroke Pines, Florida

  • Local Institution - 155

    Tampa, Florida

  • Local Institution - 136

    Atlanta, Georgia

  • Local Institution - 111

    Atlanta, Georgia

  • Local Institution - 192

    Atlanta, Georgia

  • Local Institution - 138

    Decatur, Georgia

  • Local Institution - 169

    Marietta, Georgia

  • Local Institution - 151

    Chicago, Illinois

  • Local Institution - 166

    Gaithersburg, Maryland

  • Local Institution - 187

    Boston, Massachusetts

  • Local Institution - 129

    St Louis, Missouri

  • Local Institution - 178

    St Louis, Missouri

  • Local Institution - 174

    Omaha, Nebraska

  • Local Institution - 148

    Las Vegas, Nevada

  • Local Institution - 188

    Berlin, New Jersey

Showing 40 of 94 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.